Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Oncolytics Biotech Inc
(TSX:
ONC
)
1.320
-0.030 (-2.22%)
Streaming Delayed Price
Updated: 2:30 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Oncolytics Biotech Inc
< Previous
1
2
3
4
Next >
Oncolytics Announces the Anal Cancer Cohort of the GOBLET Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for Efficacy
November 09, 2023
Pelareorep-atezolizumab combination data exceeds historical control trials with a 37.5% objective response rate, including a complete response San Diego, CA, and Calgary, AB – November 9, 2023 –...
Via
FinancialNewsMedia
Fighting the Silent Killer: Innovative Therapies for Pancreatic Cancer on the Rise
October 23, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(OTCQX:RHHBY),(NASDAQ:BNTX),(NASDAQ:ME) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
Product Safety
Oncolytics Achieves Success Criteria for Efficacy in the Third-Line Colorectal Cancer Cohort of the GOBLET Study
October 23, 2023
Results met efficacy criteria for enrollment expansion and provide support for pelareorep’s mechanism of action San Diego, CA and Calgary, AB – October 23, 2023 – Oncolytics Biotech® Inc. (NASDAQ:...
Via
FinancialNewsMedia
Rising Number of Studies to Develop Novel Therapies For Pancreatic Ductal Adenocarcinoma (PDAC) Intensely Increasing
October 23, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:CRDF),(NYSE:LLY),(NYSE:ABBV),(NASDAQ:LIPO) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Death
Exposures
Death
Oncolytics Presents Positive Updated Pancreatic Cancer Data from GOBLET Phase 1/2 Study at ESMO
October 23, 2023
7.2 months mPFS and 10.6 months interim median OS surpass historical outcomes by ≥ 25% T-cell expansion data correlate with tumor response, providing important proof-of-concept San Diego, CA and...
Via
FinancialNewsMedia
Biotech Companies Make Further Progress in Promising Pancreatic Cancer Treatment Research
October 20, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:BNTX),(NASDAQ:SGEN),(NASDAQ:MYGN),(NASDAQ:ILMN) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
Product Safety
Oncolytics Biotech® To Present Two Posters on the Pelareorep-Based GOBLET Study at ESMO 2023
October 16, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC) EQNX::TICKER_END
Via
FinancialNewsMedia
New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review
October 13, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:PYXS),(NASDAQ:AZN),(NYSE:LLY),(NASDAQ:MRUS) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
Product Safety
Young Adults and Pancreatic Cancer: What the 80% Rise in Diagnoses Means for Future Treatment
October 11, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GNLX),(NASDAQ:CRNX),(NYSE:PFE),(NASDAQ:SGEN) EQNX::TICKER_END
Via
FinancialNewsMedia
Pancreatic Cancer Research Gains Momentum Amidst Soaring Young-Onset Cases
September 26, 2023
FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 26, 2023 – USA News Group – The seriousness of pancreatic cancer continues to grow, with increasing alarm since The...
Via
FinancialNewsMedia
THE PANCREATIC CANCER ACTION NETWORK SELECTS ONCOLYTICS BIOTECH® INC. TO RECEIVE $5 MILLION THERAPEUTIC ACCELERATOR AWARD TO DEVELOP LEADING-EDGE TREATMENTS
September 26, 2023
Innovative Multimillion-Dollar Grant Was Created in 2022 to Drive Biopharma Industry to Speed Development of Pancreatic Cancer Therapies BOSTON, MA., San Diego, CA., and Calgary, AB. – September 26,...
Via
FinancialNewsMedia
Exposures
Product Safety
Investigational Immunotherapy Treatments Offering Promise in Treating Pancreatic Cancer as Risk Factors Rise
September 26, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:VACC),(NASDAQ:BPTS),(NASDAQ:RNAZ),(NYSE:BMY) EQNX::TICKER_END
Via
FinancialNewsMedia
Revolutionary Cancer Treatment Advances Promise Brighter Future Amid Federal Funding Uncertainty
September 22, 2023
FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 22, 2023 – USA News Group – Despite the potential federal funding challenges due to the recent debt ceiling deal,...
Via
FinancialNewsMedia
On the Road to Halving Cancer: The 2023 Biotech Advancements Igniting Hope
September 20, 2023
FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 20, 2023 – USA News Group – Earlier this year, the US White House requested over $2.8 billion in funding from Congress...
Via
FinancialNewsMedia
Pancreatic Cancer Battle Boosted by $200M VC Firm
September 19, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:MACK),(NASDAQ:INCY),(NASDAQ:MRTX),(NASDAQ:BNTX) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Death
Exposures
Death
Wave of FDA Fast Track Designations Highlight Biotech Momentum Carrying into 2023
September 13, 2023
FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 13, 2023 – USA News Group – Sufferers of many different ailments saw reason to grow their hope in 2022 when the US Food...
Via
FinancialNewsMedia
Exposures
Product Safety
Increased Funding for Pancreatic Cancer Trials & Treatments Rising along with Demand for New Drugs
June 22, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:POAI),(NASDAQ:AGLE),(NASDAQ:TALS),(NASDAQ:MRTX) EQNX::TICKER_END
Via
FinancialNewsMedia
Oncolytics Biotech’s® Pelareorep Selected for Inclusion in Precision PromiseSM Pivotal Phase 3 Platform Trial
June 22, 2023
Adaptive clinical trial designed to accelerate registration pathways for pancreatic cancer therapies and expected to reduce cost of a Phase 3 study for pelareorep by ~50% compared to a traditional...
Via
FinancialNewsMedia
New Drugs in Fight Against Cancer Being Powered by Novel Mechanisms of Action
June 08, 2023
FN Media Group Presents USA News Group News Commentary Vancouver, BC – June 8, 2023 – USA News Group – By utilizing newly developed novel mechanisms, biotech researchers and scientists are making...
Via
FinancialNewsMedia
Biotechs Zeroing In on Developing Breakthrough Therapeutics for Metastatic Breast Cancer
June 05, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:GILD),(NASDAQ:RAIN),(NASDAQ:CNSP),(NYSE:BMY) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
COVID-19
Oncolytics Biotech® Announces Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial that Show Pelareorep Driving Robust Increases in Progression-Free Survival and Confirmed Overall Response Rate
June 05, 2023
Pelareorep-paclitaxel combination reduced risk of disease progression by 71% (hazard ratio of 0.29) compared to paclitaxel monotherapy 37.5% confirmed overall response rate with pelareorep-paclitaxel...
Via
FinancialNewsMedia
Big Developments in Cancer Treatments set for Upcoming ASCO 2023 Annual Meeting in June
May 31, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:JAZZ),(NASDAQ:GERN),(NASDAQ:INAB),(NASDAQ:VCYT) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
Product Safety
Promising Developments Announced Ahead of 2023 ASCO Annual Meeting’s Oral Presentations
May 26, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GILD),(NASDAQ:IMGN),(NASDAQ:DAWN),(NASDAQ:LEGN) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
Product Safety
The Global Metastatic Breast Cancer Treatment Market Expected To Reach $31 Billion By 2028
May 26, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:PFE),(NASDAQ:OCEA),(NYSE:NVS),(NASDAQ:RLAY) EQNX::TICKER_END
Via
FinancialNewsMedia
Evolution of Oncology Treatments Giving New Hope to Those Diagnosed with Breast Cancer
March 24, 2023
FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 24, 2023 – USA News Group – Treatments for various forms of breast cancer continue to evolve, with several new breakthroughs...
Via
FinancialNewsMedia
Global Breast Cancer Market Size Projected To Hit $70 Billion in Revenues By 2030
May 05, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:BMY),(NASDAQ:NNOX),(NASDAQ:SNGX),(NASDAQ:CRDF) EQNX::TICKER_END
Via
FinancialNewsMedia
Rise in Biotech Innovations Generating Hope as Pancreatic Cancer Survival Rates Climb
March 14, 2023
FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 14, 2023 – USA News Group – Optimism is on the rise as the American Cancer Society is reporting that the five-year survival...
Via
FinancialNewsMedia
Exposures
Product Safety
Biotechs Race for New Treatments as Breast Cancer Therapeutics Market Could Reach $15 Billion by 2028
December 08, 2022
EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:GILD),(NYSE:BMY),(NASDAQ:RXDS),(NASDAQ:RNAZ) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
COVID-19
Oncolytics Biotech’s® Chinese Development Partner Adlai Nortye Presents Interim Clinical Data Further Demonstrating the Anti-Cancer Activity of Pelareorep-Paclitaxel Combination Therapy in HR+/HER2- Metastatic Breast Cancer at the San Antonio Breast
December 08, 2022
Thirteen of fourteen (93%) evaluable patients achieved disease control, with twelve (86%) showing tumor shrinkage San Diego, CA and Calgary, AB – December 8, 2022 – Oncolytics Biotech® Inc.’s (NASDAQ:...
Via
FinancialNewsMedia
Wave of FDA Fast Track Designations Sparks Renewed Interest in Biotech Sector That’s Heating Up
December 01, 2022
FN Media Group Presents USA News Group News Commentary Vancouver, BC –December 1, 2022 – USA News Group – A series of new Fast Track designations have been handed out by the United States Food and Drug...
Via
FinancialNewsMedia
Exposures
Product Safety
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.